Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Early Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Cyclophosphamide
Drug: GVAX Pancreas Vaccine (GVAX)
Drug: Pembrolizumab
Drug: IMC-CS4

First Posted Date: 2017-05-15

Last Posted Date: 2025-01-09

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 11

Registration Number: NCT03153410

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Phase 3

Suspended

Conditions: B Acute Lymphoblastic Leukemia

Interventions: Drug: Allopurinol
Drug: Cytarabine
Drug: Daunorubicin Hydrochloride
Drug: Vincristine Sulfate
Drug: Dexamethasone
Drug: Pegylated L-Asparaginase
Drug: Methotrexate
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Cyclophosphamide
Drug: Mercaptopurine
Biological: Rituximab
Drug: Thioguanine
Drug: Doxorubicin
Other: Laboratory Biomarker Analysis
Biological: Inotuzumab Ozogamicin

First Posted Date: 2017-05-12

Last Posted Date: 2024-12-27

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 310

Registration Number: NCT03150693

Locations: 🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
🇺🇸
Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
🇺🇸
Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States

and more 456 locations

The p53 Colorectal Cancer Trial

Phase 2

Terminated

Conditions: Colorectal Cancer Metastatic
Colorectal Cancer Stage IV
TP53 Gene Mutation

Interventions: Drug: Cyclophosphamide

First Posted Date: 2017-05-11

Last Posted Date: 2021-01-22

Lead Sponsor: Haukeland University Hospital

Target Recruit Count: 12

Registration Number: NCT03149679

Locations: 🇳🇴
Haukeland University Hospital, Bergen, Norway

CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.

Phase 1

Conditions: B Cell Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: CD19 CART

First Posted Date: 2017-05-10

Last Posted Date: 2017-05-17

Lead Sponsor: Shenzhen Second People's Hospital

Target Recruit Count: 20

Registration Number: NCT03146533

Locations: 🇨🇳
The Second People's Hospital of Shenzhen, Shenzhen, Guangdong, China

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia with BCR-ABL1
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic Leukemia

Interventions: Biological: Blinatumomab
Drug: Cyclophosphamide
Drug: Cytarabine
Biological: Filgrastim
Drug: Methotrexate
Biological: Pegfilgrastim
Drug: Ponatinib
Biological: Rituximab
Drug: Vincristine

First Posted Date: 2017-05-10

Last Posted Date: 2024-03-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 22

Registration Number: NCT03147612

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Drug: KITE-718
Drug: Cyclophosphamide
Drug: Fludarabine
Device: MAGE - A3/A6 Screening Test

First Posted Date: 2017-05-03

Last Posted Date: 2023-08-25

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 16

Registration Number: NCT03139370

Locations: 🇺🇸
Baylor Scott & White Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 9 locations

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Phase 2

Recruiting

Conditions: Recurrent Acute Lymphoblastic Leukemia
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Burkitt Leukemia
Recurrent Burkitt Lymphoma
Recurrent Childhood Lymphoblastic Lymphoma
Refractory Burkitt Leukemia
Refractory Lymphoblastic Lymphoma
Refractory Acute Lymphoblastic Leukemia
Refractory Burkitt Lymphoma

Interventions: Drug: Bortezomib
Drug: Clofarabine
Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Etoposide
Biological: Ofatumumab
Biological: Pegfilgrastim
Biological: Rituximab
Drug: Vincristine Sulfate Liposome

First Posted Date: 2017-05-02

Last Posted Date: 2024-03-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 42

Registration Number: NCT03136146

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Cyclophosphamide
Drug: Oxaliplatin
Drug: Capecitabine
Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: nab-paclitaxel
Biological: bevacizumab
Biological: avelumab
Biological: ALT-803
Biological: aNK for Infusion
Biological: ETBX-011
Biological: GI-4000

First Posted Date: 2017-05-02

Last Posted Date: 2024-06-11

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 3

Registration Number: NCT03136406

Locations: 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

Cyclophosphamide and Alemtuzumab In Lymphoma

Phase 1

Terminated

Conditions: Non Hodgkin Lymphoma
High-grade B-cell Lymphoma
Diffuse Large B Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Alemtuzumab

First Posted Date: 2017-04-28

Last Posted Date: 2019-01-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT03132584

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Phase 2

Completed

Conditions: Acute Leukemia
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Graft Versus Host Disease
Hodgkin Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Myelodysplastic Syndrome

Interventions: Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Procedure: Hematopoietic Cell Transplantation
Other: Laboratory Biomarker Analysis
Drug: Melphalan Hydrochloride
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Quality-of-Life Assessment
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2017-04-25

Last Posted Date: 2024-01-09

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 38

Registration Number: NCT03128359

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy